{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:17:41Z","timestamp":1783207061209,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR128513"],"award-info":[{"award-number":["NIHR128513"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT 220866\/Z\/20\/Z"],"award-info":[{"award-number":["WT 220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["RP-PG-0616-20008"],"award-info":[{"award-number":["RP-PG-0616-20008"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007602","name":"National Institute for Health Research Programme Grants for Applied Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.drugpo.2026.105347","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:33:36Z","timestamp":1780122816000},"page":"105347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UK"],"prefix":"10.1016","volume":"154","author":[{"given":"Zoe","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-2453","authenticated-orcid":false,"given":"Stuart Mc","family":"Pherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gillyon-Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-4476","authenticated-orcid":false,"given":"John F","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-459X","authenticated-orcid":false,"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2026.105347_bib0002","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijid.2020.09.1445","article-title":"HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities","volume":"101","author":"Avramovic","year":"2020","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1016\/j.drugpo.2026.105347_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jve.2020.06.001","article-title":"Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries","volume":"6","author":"Barber","year":"2020","journal-title":"Journal of Virus Eradication"},{"key":"10.1016\/j.drugpo.2026.105347_bib0004","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1016\/S2214-109X(23)00058-X","article-title":"Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: A systematic review","volume":"11","author":"Colledge-Frisby","year":"2023","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.drugpo.2026.105347_bib0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","article-title":"Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: A systematic review and meta-analysis","volume":"7","author":"Cunningham","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2026.105347_bib0006","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","article-title":"Cost-effectiveness of treatments for opioid use disorder","volume":"78","author":"Fairley","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugpo.2026.105347_bib0007","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/add.14267","article-title":"Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland","volume":"113","author":"Fraser","year":"2018","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.drugpo.2026.105347_bib0009","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: An updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver International: Official Journal of the International Association for the Study of the Liver"},{"key":"10.1016\/j.drugpo.2026.105347_bib0008","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: A systematic analysis for the global burden of disease study 2017","volume":"5","year":"2020","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2026.105347_bib0010","article-title":"Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: Population based cohort study","volume":"382","author":"Hamill","year":"2023","journal-title":"BMJ (Clinical Research edition)"},{"key":"10.1016\/j.drugpo.2026.105347_bib0011","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/eurpub\/ckr083","article-title":"Hepatitis C prevalence in England remains low and varies by ethnicity: An updated evidence synthesis","volume":"22","author":"Harris","year":"2012","journal-title":"European Journal of Public Health"},{"key":"10.1016\/j.drugpo.2026.105347_bib0012","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.18553\/jmcp.2022.28.10.1138","article-title":"Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective","volume":"28","author":"Kaplan","year":"2022","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1016\/j.drugpo.2026.105347_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003818","article-title":"Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis","volume":"18","author":"Lim","year":"2021","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.drugpo.2026.105347_bib0015","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.drugpo.2026.105347_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation","volume":"65","author":"Martin","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.drugpo.2026.105347_bib0016","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/jech-2016-208141","article-title":"Return on investment of public health interventions: A systematic review","volume":"71","author":"Masters","year":"2017","journal-title":"Journal of Epidemiology and Community Health"},{"key":"10.1016\/j.drugpo.2026.105347_bib0017","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12954-024-01115-6","article-title":"How far are we? Assessing progress in hepatitis C response towards the WHO 2030 elimination goals by the civil society monitoring in 25 European countries, period 2020 to 2023","volume":"21","author":"Maticic","year":"2024","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.drugpo.2026.105347_bib0001","series-title":"Guide to the methods of technology appraisal PMGP","year":"2013"},{"key":"10.1016\/j.drugpo.2026.105347_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a cochrane review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.drugpo.2026.105347_bib0021","article-title":"Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK","author":"Samartsidis","year":"2024","journal-title":"The International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2026.105347_bib0022","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S2468-1253(20)30008-X","article-title":"A model of the economic benefits of global hepatitis C elimination: An investment case","volume":"5","author":"Scott","year":"2020","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2026.105347_bib0023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/pubmed\/fdh109","article-title":"Screening for Hepatitis C in injecting drug users: A cost utility analysis","volume":"26","author":"Stein","year":"2004","journal-title":"Journal of Public Health (Oxford, England)"},{"key":"10.1016\/j.drugpo.2026.105347_bib0024","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/add.14519","article-title":"Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs","volume":"114","author":"Sweeney","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.drugpo.2026.105347_bib0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: A modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2026.105347_bib0027","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/add.14978","article-title":"Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England","volume":"115","author":"Ward","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.drugpo.2026.105347_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103394","article-title":"Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison","volume":"96","author":"Ward","year":"2021","journal-title":"The International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2026.105347_bib0028","article-title":"Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: A mathematical modelling study","volume":"49","author":"Ward","year":"2025","journal-title":"Lancet Regional Health - Europ"},{"key":"10.1016\/j.drugpo.2026.105347_bib0029","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.46.2400180","article-title":"Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: A registry-based study to monitor progress towards elimination","volume":"29","author":"Whittaker","year":"2024","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.drugpo.2026.105347_bib0018","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021: Towards ending viral hepatitis","year":"2016"},{"key":"10.1016\/j.drugpo.2026.105347_bib0030","series-title":"Guidance for country validation of viral hepatitis elimination and path to elimination: Technical report","year":"2023"},{"key":"10.1016\/j.drugpo.2026.105347_bib0019","series-title":"Global hepatitis report 2026","year":"2026"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395926001994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395926001994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T22:37:35Z","timestamp":1783204655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395926001994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"alternative-id":["S0955395926001994"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2026.105347","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UK","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2026.105347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105347"}}